| |
| | XELODA (capecitabine) Oral Chemotherapy Tablets – Home Page |
 | | Breast Cancer Combination Therapy: XELODA in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. |
 | | Breast Cancer Monotherapy: XELODA monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated, eg, patients who have received cumulative doses of 400 mg/m |
 | | In XELODA monotherapy for metastatic breast cancer, the most common adverse events (≥10%) were lymphopenia (94), anemia (72), diarrhea (57), hand-foot syndrome (57), nausea (53), fatigue (41), vomiting (37), dermatitis (37), neutropenia (26), thrombocytopenia (24), stomatitis (24), anorexia (23), hyperbilirubinemia (22), paresthesia (21), abdominal pain (20), eye irritation (15), constipation (15), and pyrexia (12). |
| www.xeloda.com |
|